menu

Communicating Genetic Testing Results to AMKD Patients: The Impact of Early Diagnosis

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Improving Outcomes in APOL1-Mediated Kidney Disease Patients: The Need for New Treatments

Communicating Genetic Testing Results to AMKD Patients: The Impact of Early Diagnosis

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    This program discusses the need to increase awareness about APOL1-Mediated Kidney Disease (AMKD), the clinical impact of genotyping for early diagnosis, disease management, and the need for new small-molecule drug treatments. There is currently a lack of awareness among key decision-makers and in the Black community regarding the health disparities and the importance of genotyping in AMKD. Increasing awareness among nephrologists, hospitalists, geneticists, and patient communities on the impact of early genotyping for APOL1 in Black patients have the potential to improve outcomes and reduce health disparities. Moreover, increasing awareness among nephrologists and patient networks may improve clinical trial participation among underrepresented communities, which can directly impact the development of new AMKD treatments.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including nephrologists, hospitalists, geneticists, as well as other clinicians, involved in the management of patients with about APOL1-Mediated Kidney Disease (AMKD).

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Outline the clinical manifestations, causes, and pathogenesis of AMKD
    • Explain the value of genotyping for APOL1 variants and risk assessment for early diagnosis
    • Illustrate the patient experience of AMKD, with a focus on disease burden, current disease management strategies, and the importance of new treatments
  • Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.

    The following faculty have disclosed:

    Adriana Hung, MD, MPH, faculty for this educational event, has no relevant financial relationships with ineligible companies.

    Csaba P. Kovesdy, MD, chair for this educational event, received research funding from AstraZeneca, Bayer, Gilead, and GSK; and received consulting fees from Abbott, AstraZeneca, Akebia, Bayer, Boehringer Ingelheim, Cara Therapeutics, CSL Behring, GSK, Rockwell, and Vifor.

    Martin Pollak, MD, faculty for this educational event, received research funding from Vertex; has ownership interest in Apolo1Bio; receives royalties from Athena Diagnostics; and received consulting fees from Vertex.

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Vertex Pharmaceuticals Incorporated.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 12/21/2022 through 12/21/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%.
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.
  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule22 Sep 2023